Table 4.
Estimated present value of future lifetime productivity due to HPV-attributable cancer deaths by sex and HPV type (in thousands, 2017 $).
| PVFLP By Sex and Cancer Site (% of Total PVFLP) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | Women | Men | |||||||
| Cervix | Vagina | Vulva | Anus | Oropharynx | Penis | Anus | Oropharynx | ||
| Any HPV | 4,215,447 (100) | 2,847,795 (67.6) | 90,885 (2.2) | 256,211 (6.1) | 291,883 (6.9) | 73,389 (1.7) | 100,938 (2.4) | 232,742 (5.5) | 321,605 (7.6) |
| HPV 16/18 | 3,203,913 (76.0) | 2,080,839 (49.4) | 66,770 (1.6) | 180,986 (4.3) | 250,861 (6.0) | 58,896 (1.4) | 76,381 (1.8) | 207,553 (4.9) | 281,626 (6.7) |
| HPV 31/33/45/52/58 | 626,077 (14.9) | 462,059 (11.0) | 22,176 (0.5) | 52,881 (1.3) | 34,079 (0.8) | 11,014 (0.3) | 14,351 (0.3) | 9,971 (0.2) | 19,545 (0.5) |
| PVFLP per death | 595 | 747 | 295 | 295 | 431 | 404 | 453 | 600 | 512 |
HPV, human papillomavirus; PVFLP, present value of future lifetime productivity.